GCP
ECYT

GSA Capital Partners’s Endocyte, Inc. Common Stock ECYT Stock Holding History

GSA Capital Partners’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-16,335
Closed -$389K – 2046
2014
Q1 		$389K Buy
+16,335
New +$237K 0.03% 947
2013
Q4 		– Sell
-16,235
Closed -$216K – 1844
2013
Q3 		$216K Buy
+16,235
New +$257K 0.02% 1352

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BB Biotech
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pinnacle Associates
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PAAMCP
Pacific Alternative Asset Management Company (PAAMCO) Irvine, California $913M AUM 18.29% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

GSA Capital Partners's ECYT Position: Q2 2014 in Review

GSA Capital Partners sold out of Endocyte, Inc. Common Stock (ECYT) in Q2 2014, closing a stake of 16,335 shares — an estimated $389K sold.

GSA Capital Partners first reported a position in ECYT in Q3 2013 and held it in 2 quarters. The position peaked at $389K in Q1 2014. 101 funds tracked by Wall St. Rank hold ECYT as of Q2 2014.

  • GSA Capital Partners reported no remaining Endocyte, Inc. Common Stock position as of Q2 2014 after selling out during the quarter.
  • GSA Capital Partners sold 16,335 Endocyte, Inc. Common Stock shares in Q2 2014, an estimated $389K.
  • GSA Capital Partners first reported a position in Endocyte, Inc. Common Stock in Q3 2013 and held it in 2 quarters.
  • GSA Capital Partners's Endocyte, Inc. Common Stock position peaked at $389K in Q1 2014.
  • 101 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q2 2014.

Based on GSA Capital Partners's 13F filing for Q2 2014, filed 8 Aug 2014.